History of Hologic in Timeline

Hologic, Inc. is a medical technology company based in the United States. Its core focus is women's health, and it develops, manufactures, and sells medical devices used in diagnostics, surgical procedures, and medical imaging. The company aims to improve women's health and well-being through its innovative products and services.

November 2013: Carl Icahn discloses stake in Hologic

In November 2013, activist investor Carl Icahn disclosed a 12.5% stake in Hologic, which led to the company adopting a poison pill to prevent a hostile takeover and negotiations with the board.

March 3, 2016: Icahn's nominees resign from Hologic board

On March 3, 2016, Carl Icahn's nominees to the Hologic board of directors resigned, marking a successful intervention by Icahn into the company.

May 16, 2016: Icahn exits Hologic position

On May 16, 2016, Carl Icahn exited his position in Hologic, considering his investment and intervention into the company a success.

2017: Hologic acquires Cynosure

In 2017, Hologic acquired Cynosure, an aesthetic medicine company based in Westford, Massachusetts, for $1.65 billion.

November 20, 2019: Hologic announces divestment of Cynosure

On November 20, 2019, Hologic announced the divestment of Cynosure to Clayton, Dubilier & Rice for $205 million.

December 30, 2019: Hologic completes divestment of Cynosure

On December 30, 2019, Hologic completed the divestment of Cynosure to Clayton, Dubilier & Rice, with Cynosure having approximately 825 employees at the time.

2019: COVID-19 Pandemic

In 2019, the COVID-19 pandemic began.

March 2020: Hologic receives emergency use authorization for SARS-CoV-2 test

In March 2020, Hologic received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic.

May 2020: Hologic receives second emergency use authorization for 2019-nCov

In May 2020, Hologic received a second emergency use authorization from the FDA for 2019-nCov to increase potential throughput of testing.

June 2020: Hologic collaborates with Grifols to increase COVID-19 testing capacity in Spain

In June 2020, Hologic collaborated with Grifols, a global producer of plasma-driven medicines, to increase Spain's testing capacity for COVID-19.

November 2020: Hologic wins contract to expand COVID-19 test production

In November 2020, Hologic won a $119 million contract from the U.S. Department of Health and Human Services and the Department of Defense to help expand production facilities in Wisconsin, Maine, and California.

January 2021: Hologic announces acquisition of Biotheranostics and SOMATEX

In January 2021, Hologic announced it would acquire Biotheranostics and its breast and metastatic cancer test portfolio for $230 million and SOMATEX for $64 Million.

April 2021: Hologic announces acquisition of Mobidiag

In April 2021, Hologic announced it will acquire Mobidiag, a molecular diagnostics firm with multiplex technology, for $795 million.

June 2021: Hologic completes acquisition of Mobidiag

In June 2021, Hologic completed the acquisition of Mobidiag, a molecular diagnostics firm with multiplex technology, for $795 million.

January 2022: Goal to provide 13 million COVID tests per month

By January 2022, the goal was to provide 13 million COVID tests per month, as part of Hologic's contract with the U.S. Department of Health and Human Services and the Department of Defense.

March 2022: Hologic becomes title sponsor of WTA Tour

In March 2022, Hologic became the title sponsor of the WTA Tour in women's professional tennis and was named the "official health partner" of the Women's Tennis Association.